• 1
    Ferlay J,Bray F,Pisani P,Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide, IARC CancerBase No. 5. Version 2.0. Lyon: IARC Press, 2004.
  • 2
    Kjaer SK,Chackerian B,van den Brule AJ,Svare EI,Paull G,Walbomers JM,Schiller JT,Bock JE,Sherman ME,Lowy DR,Meijer CL. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev 2001; 10: 1016.
  • 3
    Walboomers JM,Jacobs MV,Manos MM,Bosch FX,Kummer JA,Shah KV,Snijders PJ,Peto J,Meijer CJ,Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 1219.
  • 4
    Baseman JG,Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32( Suppl 1): 1624.
  • 5
    Kjaer SK,van den Brule AJ,Paull G,Svare EI,Sherman ME,Thomsen BL,Suntum M,Bock JE,Poll PA,Meijer CJ. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002; 325: 5728.
  • 6
    Munoz N,Bosch FX,de Sanjose S,Herrero R,Castellsague X,Shah KV,Snijders PJ,Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 51827.
  • 7
    Smith JS,Lindsay L,Hoots B,Keys J,Franceschi S,Winer R,Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions. A meta-analysis update. Int J Cancer 2007; 121: 62132.
  • 8
    Castellsague X,Diaz M,de Sanjose S,Munoz N,Herrero R,Franceschi S,Peeling RW,Ashley R,Smith JS,Snijders PJ,Meijer CJ,Bosch FX, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006; 98: 303315.
  • 9
    Muñoz N,Castellsagué X,Berrington de Gonzales A,Gissmann L. HPV in the etiology of human cancer. Vaccine 2006; 24( Suppl 3): 110.
  • 10
    Lacey CJN,Lowndes CM,Shah KV. HPV vaccines and screening in the prevention of cervical cancer. Vaccine 2006; 24( Suppl 3): 3541.
  • 11
    The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 191527.
  • 12
    Garland SM,Hernandez-Avilla M,Wheeler C,Perez G,Harper DM,Leodolter S,Tang GW,Ferris DG,Steben M,Bryan J,Taddeo FJ,Railkar R, et al., Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 192843.
  • 13
    Harper DM,Franco EL,Wheeler C,Ferris DG,Jenkins D,Schuind A,Zahaf T,Innis B,Naud P,De Carvalho NS,Roteli-Martins CM,Teixeira J, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 175765.
  • 14
    Munk C,Kjaer SK,Poll P,Bock JE. Cervical cancer screening: knowledge of own screening status among women aged 20–29 years. Acta Obstet Gynecol Scand 1998; 77: 91722.
  • 15
    Vernick JP,Steigman CK. The HPV DNA virus hybrid capture assay. What is it and where to we go from here? Med Lab Obs 2003; 35: 810.
  • 16
    Iftner T,Villa LL. Chapter 12: human papillomavirus technologies. J Natl Cancer Inst Monogr 2003; 31: 808.
  • 17
    Kitchener HC,Almonte M,Wheeler P,Desai M,Gilham C,Bailey A,Sargent A,Peto J,for the ARTISTIC Trial Study Group. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 2006; 95: 5661.
  • 18
    Dunne EF,Unger ER,Sternberg M,McQuillan G,Swan DC,Patel SS,Markowitz LE. Prevalence of HPV infection among females in the United States. JAMA 2007; 297: 81319.
  • 19
    Herrero R,Castle P,Schiffman M,Bratti MC,Hildesheim A,Morales J,Alfaro M,Sherman M,Wacholder S,Chen S,Rodriques AC,Burk RD. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005; 191: 1796807.
  • 20
    Nielsen A,Kjaer SK,Munk C,Iftner T. Type-specific HPV infection and multiple HPV types: prevalence and risk factor profile in nearly 12,000 younger and older Danish women. Sex Transm Dis 2008; 35: 27682.
  • 21
    Clifford GM,Rana RK,Franceschi S,Smith JS,Gough G,Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 115764.
  • 22
    Clifford GM,Smith JS,Aguado T,Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89: 1015.
  • 23
    Clifford GM,Gallus S,Herrero R,Muñoz N,Snijders PJF,Vaccarella S,Anh PTH,Ferreccia C,Hieu NT,Matos E,Molano M,Rajkumar R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366: 9918.
  • 24
    Hwang HS,Park M,Lee SY,Kwon KH,Pang MG. Distribution and prevalence of human papillomavirus genotypes in routine pap smear of 2,470 Korean women determined by DNA chip. Cancer Epidemiol Biomarkers Prev 2004; 13: 21536.
  • 25
    van Doorn LJ,Quint W,Kleter B,Molijn A,Colau B,Martin MT,Kravang I,Torrez-Martinez N,Peyton CL,Wheeler CM. Genotyping of human papillomavirus in liquid cytology cervical specimens by PGMY line blot assay and the SPF(10) line probe assay. J Clin Microbiol 2002; 40: 97983.
  • 26
    Kleter B,van Doorn LJ,Schrauwen L,Molijn A,Sastrowijoto S,ter Schegget J,Lindeman J,ter Harmsel B,Burger M,Quint W. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999; 37: 250817.
  • 27
    Klug S,Molijn A,Schopp B,Holz B,Iftner A,Quint W,Snijders P,Petry K-U,Krüger Kjær S,Munk C,Iftner T. Comparison of the performance of different HPV genotyping methods for detection of genital HPV types. J Med Virol 2008; 80: 126474.
  • 28
    Prétet JL,Jacquard AC,Carcopino X,Monnier-Benoit S,Averous G,Soubeyrand B,Leocmach Y,Mougin C,Riethmuller D, EDITH study group. Human papillomavirus genotype distribution in high grade cervical lesions (CIN 2/3) in France: EDITH study. Int J Cancer 2008; 122: 4247.
  • 29
    Franceschi S,Herrero R,Clifford GM,Snijders P,Arslan A,Anh PTH,Bosch FX,Ferreccio C,Hieu NT,Lazcano-Ponce E,Matos E,Molano M, et al. Variations in the age-specific curves of human papillomavirus prevalence worldwide. Int J Cancer 2006; 119: 267784.
  • 30
    Cuschieri KS,Cubie HA,Whitley MW,Seagar AL,Arends MJ,Moore C,Gilkisson G,Mcgoogan E. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol 2004; 57: 6872.
  • 31
    Rolon PA,Smith JS,Munoz N,Klug SJ,Herrero R,Bosch X,Llamosas F,Meijer CJ,Quintana MJ. Human papillomavirus infection and invasive cervical cancer in Paraguay. Int J Cancer 2000; 85: 48691.
  • 32
    Anttila A,Ronco G,Clifford,Bray F,Hakama M,Arbyn M,Weiderpass E. Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer 2004; 91: 93541.